TScan Therapeutics, Inc. Quarterly Debt-to-equity in % from Q1 2022 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
TScan Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q1 2022 to Q3 2024.
  • TScan Therapeutics, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 63 %, a 23.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 63 -19.7 -23.8% Sep 30, 2024
Q2 2024 68.9 -7.46 -9.76% Jun 30, 2024
Q1 2024 77 +14.8 +23.9% Mar 31, 2024
Q4 2023 79.1 +40.3 +104% Dec 31, 2023
Q3 2023 82.7 +61.2 +284% Sep 30, 2023
Q2 2023 76.4 +59.8 +361% Jun 30, 2023
Q1 2023 62.2 +35.7 +135% Mar 31, 2023
Q4 2022 38.9 Dec 31, 2022
Q3 2022 21.5 Sep 30, 2022
Q2 2022 16.6 Jun 30, 2022
Q1 2022 26.5 Mar 31, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.